For a better experience, Read this story in our App
TO ENJOY ADDITIONAL BENEFITS
Connect With Us
Get BusinessLine apps on
The partnership helps expand Lupin’s footprint in China. | Photo Credit: DANISH SIDDIQUI
Drugmaker Lupin Ltd has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialisation of Tiotropium Dry Powder Inhaler (DPI) in China, for the treatment of chronic obstructive pulmonary disease (COPD).
SUP will get the regulatory approvals for selling Tiotropium DPI (18 mcg/capsule) in China, while Lupin will be the marketing authorisation holder, responsible for manufacturing of the product, Lupin said. The partnership helps expand Lupin’s footprint in China, it said.
Tiotropium DPI is known for its efficacy in improving lung function and the quality of life for patients suffering from respiratory conditions, a note from the company said.
Fabrice Egros, Lupin President (Corporate Development), said the partnership demonstrated its commitment to developing critical products for the treatment of respiratory diseases such as COPD. Wang Li, President of SUP, added, the collaboration would strengthen their synergy in respiratory care. “By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.”
Published on June 16, 2025
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.